SMIM1 and neoplasm: First, through integration with transcriptome data from both CRC cell lines and primary tumours, we find that the recurrently acquired enhancers activate genes that are commonly elevated in CRC, suggesting VEL acquisition is a major mechanism by which tumour cells alter expression to gain a growth or survival advantage.